Reduction in Kawasaki Disease After Nonpharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Authors: Ji-Man Kang, Young-Eun Kim, Kyungmin Huh, Jinwook Hong, Dong Wook Kim, Min Young Kim, Se Yong Jung, Jong-Hun Kim, Jaehun Jung, Jong Gyun Ahn
Journal: Circulation (2021)

HomeCirculationVol. 143, No. 25Reduction in Kawasaki Disease After Nonpharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBReduction in Kawasaki Disease After Nonpharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea Ji-Man Kang, Young-Eun Kim, Kyungmin Huh, Jinwook Hong, Dong Wook Kim, Min Young Kim, Se Yong Jung, Jong-Hun Kim, Jaehun Jung and Jong Gyun Ahn Ji-Man KangJi-Man Kang Department of Pediatrics, Severance Children's Hospital (J.-M.K., M.Y.K., J.G.A.), Yonsei University College of Medicine, Seoul, South Korea. Institute for Immunology and Immunological Diseases (J.-M.K., M.Y.K., J.G.A.), Yonsei University College of Medicine, Seoul, South Korea. , Young-Eun KimYoung-Eun Kim https://orcid.org/0000-0003-0694-6844 Department of Big Data Strategy, National Health Insurance Service, Wonju, South Korea (Y.-E.K., D.W.K.). , Kyungmin HuhKyungmin Huh Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (K.H.). , Jinwook HongJinwook Hong Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center (J.H., J.J.), Gachon University College of Medicine, Incheon, South Korea. , Dong Wook KimDong Wook Kim Department of Big Data Strategy, National Health Insurance Service, Wonju, South Korea (Y.-E.K., D.W.K.). , Min Young KimMin Young Kim Department of Pediatrics, Severance Children's Hospital (J.-M.K., M.Y.K., J.G.A.), Yonsei University College of Medicine, Seoul, South Korea. Institute for Immunology and Immunological Diseases (J.-M.K., M.Y.K., J.G.A.), Yonsei University College of Medicine, Seoul, South Korea. , Se Yong JungSe Yong Jung Division of Pediatric Cardiology, Department of Pediatrics (S.Y.J.), Yonsei University College of Medicine, Seoul, South Korea. , Jong-Hun KimJong-Hun Kim Department of Social and Preventive Medicine, Sungkyunkwan University School of Medicine, Suwon, Gyeonggi-do, South Korea (J.-H.K.). , Jaehun JungJaehun Jung Jaehun Jung, MD, PhD, Assistant Professor, Department of Preventive Medicine, Gachon University College of Medicine, PO Box 21565, Incheon, South Korea. Email E-mail Address: [email protected] https://orcid.org/0000-0002-4856-3668 Artificial Intelligence and Big-Data Convergence Center, Gil Medical Center (J.H., J.J.), Gachon University College of Medicine, Incheon, South Korea. Department of Preventive Medicine (J.J.), Gachon University College of Medicine, Incheon, South Korea. and Jong Gyun AhnJong Gyun Ahn Correspondence to: Jong Gyun Ahn, MD, PhD, Associate Professor, Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, PO Box 03722, Seoul, South Korea; Email E-mail Address: [email protected] https://orcid.org/0000-0001-5748-0015 Department of Pediatrics, Severance Children's Hospital (J.-M.K., M.Y.K., J.G.A.), Yonsei University College of Medicine, Seoul, South Korea. Institute for Immunology and Immunological Diseases (J.-M.K., M.Y.K., J.G.A.), Yonsei University College of Medicine, Seoul, South Korea. Originally published7 Jun 2021https://doi.org/10.1161/CIRCULATIONAHA.121.054785Circulation. 2021;143:2508–2510Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: June 7, 2021: Ahead of Print Kawasaki disease (KD) is an acute febrile vasculitis of childhood of unknown cause.1 As the coronavirus disease 2019 (COVID-19) pandemic continues, many countries have implemented nonpharmaceutical interventions (NPIs) to mitigate the spread of the virus. In Korea, NPIs such as mandatory mask wearing, school closure, and testing and isolation of symptomatic individuals were implemented in February 2020, with good compliance.2 On-site school reopening was postponed until May 20, 2020, and schools were reopened gradually until June 6, maintaining strict policies such as physical distancing and restrictions on private education and group activities.2 This nationwide intervention provided a unique opportunity for us to investigate the collateral effect of NPIs on the incidence of other diseases. We aimed to investigate whether NPIs were associated with a change in KD incidence in Korea, the country with the second-highest KD incidence rate worldwide.In this retrospective, ecologic study, data on all KD cases among children 0 to 19 years of age from January 2010 to September 2020 were collected using the National Health Insurance Service database. The NPI period was defined as February through September 2020. The KD incidence rate in the NPI period was compared with the annual mean incidence rate during the same months in the pre-NPI period and with the incidence rate predicted by the autoregressive integrated moving average model. KD was defined as a case where the International Classification of Diseases–10 diagnostic code for KD (M30.3) and the prescription code for intravenous immunoglobulin (IVIg) were claimed together. IVIg-resistant KD was defined as recrudescent or persistent fever 24 to 48 hours after the first IVIg infusion, requiring an IVIg prescription nonconsecutively for at least 3 days. These data are licensed for this analysis only, and the institutional review board approved the study.A total of 53 424 cases of KD were identified; among these, 83% occurred in children <5 years of age, and 17% were resistant to IVIg. In the pre-NPI period, the annual mean incidence was 48.1 per 100 000 persons and the monthly mean incidence was 4.1/100 000 (Figure [A]). After NPI implementation, KD incidence declined sharply; from April onward, it plateaued (Figure [B]). KD incidence is typically seasonal, with a minor peak in the late spring and summer and a larger one in the winter; however, this seasonal pattern was absent in the NPI period. When considering the months from February to September, the incidence in the NPI period was 18.8/100 000, corresponding to 60% of the mean incidence (31.5/100 000) in the pre-NPI period (P=0.085) and 58% of the predicted incidence (32.2/100 000 [95% CI, 46.6–77.9%]). The incidence in children between 0 and 4 years of age, the group with the highest incidence rate, was 80.0/100 000, significantly lower than the mean incidence in the pre-NPI period (123.0/100 000; P=0.003) and the predicted incidence (123.3/100 000 [95% CI, 51.9–86.7%]; Figure [C]). In the 5 to 9 years of age group, the incidence (10.6/100 000) was also significantly lower than the mean incidence (23.8/100 000) in the pre-NPI period (P=0.04) and the predicted incidence (24.7/100 000 [95% CI, 30.9–70.6%]; Figure [D]). However, there was no difference in the incidence before and after NPI implementation in the 10 to 19 years of age group, the group with the lowest incidence (Figure [E]).Download figureDownload PowerPointFigure. Kawasaki disease (KD) incidence in Korea.A, Yearly incidence of KD from 2010 to 2020. The red line denotes the age-specific incidence of KD, and the blue line denotes the age-specific incidence of intravenous immunoglobulin (IVIg)–resistant KD. The dotted line represents February 2020, when nonpharmaceutical interventions (NPIs) were implemented in Korea owing to coronavirus disease 2019 (COVID-19). B through E, Monthly incidence of KD and incidence predicted by an autoregressive integrated moving average model. The thick red line denotes the observed incidence during the NPI period, the thick blue line denotes the predicted incidence in the NPI period, and blue shades represent 80% and 95% CIs of the predicted incidence in the NPI period.The incidence of IVIg-resistant KD had been increasing since 2018 in the pre-NPI period (Figure [A]), whereas the overall KD incidence did not change significantly (post/pre-NPI slope coefficient=0.04, P<0.0001). There was no significant change in the incidence of IVIg-resistant KD during the NPI period (6.8/100 000) compared with the annual mean of the previous 10 years (5.1/100 000; P>0.99).The reasons for the association of NPI-related factors and KD incidence decrease are unclear. A reduction in respiratory viral infections and climate change, which have been cited as potential external triggers, were also associated with our findings.2–4 The incidence of KD-like diseases such as adenovirus infection and measles, which cause febrile rashes that can mimic KD, decreased after implementation of NPIs; this association may have created a bias.2 However, the proportion of IVIg-resistant KD, a severe form of KD, did not change in 2020 compared with that in 2019 (37.7% and 36.2%, respectively; P=0.28). This finding suggests that the decrease of KD-like diseases, generally milder than KD, had little effect on the overall decrease in the incidence of KD. Nevertheless, the KD incidence rate in Korea (80/100 000 children <5 years of age) is 3 to 16 times higher than that in Western countries (5 to 25/100 000 children <5 years of age), even after NPI implementation.1,5 This difference suggests that other variables, such as genetic and ethnic factors, are important in the pathogenesis of KD, regardless of the effect of NPIs.5This nationwide study reveals that the KD incidence decreased significantly after the implementation of NPIs in Korea. Further long-term research is needed to determine whether the decrease in incidence of KD is solely attributable to the effects of NPIs.AcknowledgmentsThis study used the National Health Information Database (NHIS-2020-1-572) from the National Health Insurance Service. Drs Kang, Y.-E. Kim, J. Jung, and Ahn had full access to the study data and take responsibility for its integrity and accuracy of the analysis. Drs Kang and Y.-E. Kim contributed equally to this study. Drs Ahn, J. Jung, and Kang contributed to study concept and design. Drs Y.-E. Kim, Huh, J.-H. Kim, S.Y. Jung, J. Jung, Ahn, and Kang and M.Y. Kim and J. Hong contributed to acquisition, analysis, and interpretation of data. Drs Ahn, J. Jung, and Kang contributed to drafting of the manuscript. Drs Huh and J. Jung and J. Hong contributed to statistical analysis.Sources of FundingThis study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (grant number 2019032869) and Gachon University Gil Medical Center (grant number 2019-11). The sponsor of the study was not involved in the study design, analysis, and interpretation of data; writing of the report; or the decision to submit the study results for publication.Disclosures None.Footnotes*J.-M. Kang and Y.-E. Kim contributed equally to this article.https://www.ahajournals.org/journal/circFor Sources of Funding and Disclosures, see page 2510.Correspondence to: Jong Gyun Ahn, MD, PhD, Associate Professor, Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, PO Box 03722, Seoul, South Korea; Email jgahn@yuhs.acJaehun Jung, MD, PhD, Assistant Professor, Department of Preventive Medicine, Gachon University College of Medicine, PO Box 21565, Incheon, South Korea. Email eastside1st@gmail.comReferences1. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association.Circulation. 2017; 135:e927–e999. doi: 10.1161/CIR.0000000000000484LinkGoogle Scholar2. Huh K, Jung J, Hong J, Kim M, Ahn JG, Kim JH, Kang JM. Impact of nonpharmaceutical interventions on the incidence of respiratory infections during the coronavirus disease 2019 (COVID-19) outbreak in Korea: a nationwide surveillance study.Clin Infect Dis. 2021; 72:e184–e191. doi: 10.1093/cid/ciaa1682CrossrefMedlineGoogle Scholar3. Burns JC, Cayan DR, Tong G, Bainto EV, Turner CL, Shike H, Kawasaki T, Nakamura Y, Yashiro M, Yanagawa H. Seasonality and temporal clustering of Kawasaki syndrome.Epidemiology. 2005; 16:220–225. doi: 10.1097/01.ede.0000152901.06689.d4CrossrefMedlineGoogle Scholar4. Rodó X, Curcoll R, Robinson M, Ballester J, Burns JC, Cayan DR, Lipkin WI, Williams BL, Couto-Rodriguez M, Nakamura Y, et al. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan.Proc Natl Acad Sci U S A. 2014; 111:7952–7957. doi: 10.1073/pnas.1400380111CrossrefMedlineGoogle Scholar5. Elakabawi K, Lin J, Jiao F, Guo N, Yuan Z. Kawasaki disease: global burden and genetic background.Cardiol Res. 2020; 11:9–14. doi: 10.14740/cr993CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By LEE S, ERDEM G and YASUHARA J Multisystem inflammatory syndrome in children associated with COVID-19: from pathophysiology to clinical management and outcomes, Minerva Pediatrics, 10.23736/S2724-5276.23.07205-1, 76:2 Kim H, Jang H, Lee W, Oh J, Lee J, Kim M, Lee J, Kim H, Lee J, Ha E, Kim H, Lee W, Kim E, Kang C, Song I, Jang H, Min J, Kwon D, Oh J, Moon J, Park J, Kim A and Ahn S (2024) Association between long-term PM2.5 exposure and risk of Kawasaki disease in children: A nationwide longitudinal cohort study, Environmental Research, 10.1016/j.envres.2023.117823, 244, (117823), Online publication date: 1-Mar-2024. Edison K, Pepelassis D, Soni R, Schantz D and Buffo I (2024) Acute rheumatic fever in the province of Manitoba, Canada, before and after the coronavirus (COVID-19) pandemic, Annals of the Rheumatic Diseases, 10.1136/ard-2023-225294, (ard-2023-225294) Martin S, Aday A, Almarzooq Z, Anderson C, Arora P, Avery C, Baker-Smith C, Barone Gibbs B, Beaton A, Boehme A, Commodore-Mensah Y, Currie M, Elkind M, Evenson K, Generoso G, Heard D, Hiremath S, Johansen M, Kalani R, Kazi D, Ko D, Liu J, Magnani J, Michos E, Mussolino M, Navaneethan S, Parikh N, Perman S, Poudel R, Rezk-Hanna M, Roth G, Shah N, St-Onge M, Thacker E, Tsao C, Urbut S, Van Spall H, Voeks J, Wang N, Wong N, Wong S, Yaffe K and Palaniappan L (2024) 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association, Circulation, 149:8, (e347-e913), Online publication date: 20-Feb-2024. Lu G, Li X, Tang J, Jin Y, Wang Y, Zhou K and Li Y (2024) Mycoplasma infection aggravates cardiac involvements in Kawasaki diseases: a retrospective study, Frontiers in Immunology, 10.3389/fimmu.2023.1310134, 14 Sakai-Bizmark R, Estevez D, Wu F, Marr E, BenDavid E, Mena L and Chang R (2023) Kawasaki Disease Before and During the COVID-19 Pandemic: A Nationwide Population-based Study in the United States, Pediatric Infectious Disease Journal, 10.1097/INF.0000000000004095, 43:1, (7-13), Online publication date: 1-Jan-2024. Fukuda S, Tanaka S, Kawakami C, Kobayashi T, Ito S, Kamijima M, Yamazaki S, Ohya Y, Kishi R, Yaegashi N, Hashimoto K, Mori C, Ito S, Yamagata Z, Inadera H, Nakayama T, Sobue T, Shima M, Kageyama S, Suganuma N, Ohga S and Katoh T (2023) Maternal Serum Folic Acid Levels and Onset of Kawasaki Disease in Offspring During Infancy, JAMA Network Open, 10.1001/jamanetworkopen.2023.49942, 6:12, (e2349942) Rowley A, Arrollo D, Shulman S, Torres A, O'Brien A, Wylie K, Kim K and Baker S (2023) Analysis of Plasmablasts From Children With Kawasaki Disease Reveals Evidence of a Convergent Antibody Response to a Specific Protein Epitope, The Journal of Infectious Diseases, 10.1093/infdis/jiad048, 228:4, (412-421), Online publication date: 16-Aug-2023. Noval Rivas M and Arditi M (2023) Kawasaki Disease and Multisystem Inflammatory Syndrome in Children, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2023.03.002, 49:3, (647-659), Online publication date: 1-Aug-2023. Rand K, Bhaduri-McIntosh S, Gurka M, Chi X and Harris A (2023) Is Kawasaki Disease Caused by a Respiratory Virus?, Pediatric Infectious Disease Journal, 10.1097/INF.0000000000003889, 42:6, (468-472), Online publication date: 1-Jun-2023. Lin J, Harahsheh A, Raghuveer G, Jain S, Choueiter N, Garrido-Garcia L, Dahdah N, Portman M, Misra N, Khoury M, Fabi M, Elias M, Dionne A, Lee S, Tierney E, Ballweg J, Manlhiot C and McCrindle B (2023) Emerging Insights Into the Pathophysiology of Multisystem Inflammatory Syndrome Associated With COVID-19 in Children, Canadian Journal of Cardiology, 10.1016/j.cjca.2023.01.002, 39:6, (793-802), Online publication date: 1-Jun-2023. Liu X, Luo T, Fan Z, Li J, Zhang Y, Lu G, Lv M, Lin S, Cai Z, Zhang J, Zhou K, Guo J, Hua Y, Zhang Y and Li Y (2023) Single cell RNA-seq resolution revealed CCR1+/SELL+/XAF+ CD14 monocytes mediated vascular endothelial cell injuries in Kawasaki disease and COVID-19, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 10.1016/j.bbadis.2023.166707, 1869:5, (166707), Online publication date: 1-Jun-2023. Choi Y, Jung H, Kim H and Jeong S (2023) Changes in the Incidence of Immune Thrombocytopenia in the Coronavirus Disease 2019 Era: A Nationwide Observational Study in Korea, Risk Management and Healthcare Policy, 10.2147/RMHP.S403196, Volume 16, (667-676) Ahn S, Eun S, Ji S, Hong S, Lee C, Yoo B, Oh J and Kim Y (2023) Incidence of rheumatic diseases during the COVID-19 pandemic in South Korea, The Korean Journal of Internal Medicine, 10.3904/kjim.2022.135, 38:2, (248-253), Online publication date: 1-Mar-2023. Tsao C, Aday A, Almarzooq Z, Anderson C, Arora P, Avery C, Baker-Smith C, Beaton A, Boehme A, Buxton A, Commodore-Mensah Y, Elkind M, Evenson K, Eze-Nliam C, Fugar S, Generoso G, Heard D, Hiremath S, Ho J, Kalani R, Kazi D, Ko D, Levine D, Liu J, Ma J, Magnani J, Michos E, Mussolino M, Navaneethan S, Parikh N, Poudel R, Rezk-Hanna M, Roth G, Shah N, St-Onge M, Thacker E, Virani S, Voeks J, Wang N, Wong N, Wong S, Yaffe K and Martin S (2023) Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association, Circulation, 147:8, (e93-e621), Online publication date: 21-Feb-2023. Folga B, Karpenko C and Grygiel-Górniak B (2022) SARS-CoV-2 infection in the context of Kawasaki disease and multisystem inflammatory syndrome in children, Medical Microbiology and Immunology, 10.1007/s00430-022-00756-3, 212:1, (3-12), Online publication date: 1-Feb-2023. Kim J, Hong K, Yoo D and Chun B (2023) Spatiotemporal clusters of Kawasaki disease in South Korea from 2008 to 2017: A municipal-level ecological study, Frontiers in Pediatrics, 10.3389/fped.2022.1054985, 10 Lee Y (2023) Research trends on causes of Kawasaki disease in the COVID-19 era: focus on viral infections, Clinical and Experimental Pediatrics, 10.3345/cep.2022.00150, 66:1, (1-11), Online publication date: 15-Jan-2023. Kim S, Kim Y, Bang T, Hong M, Radnaabaatar M, Huh K, Hong K and Jung J (2023) Nationwide Trends in Non-COVID-19 Infectious Disease Laboratory Tests in the Era of the COVID-19 Pandemic in Korea, Journal of Korean Medical Science, 10.3346/jkms.2023.38.e408, 38:47 Son M and Newburger J (2022) SARS-CoV-2–Related Mitigation Measures and Insights Into Kawasaki Disease, JAMA Pediatrics, 10.1001/jamapediatrics.2022.3765, 176:12, (1167), Online publication date: 1-Dec-2022. Ae R, Makino N, Kuwabara M, Matsubara Y, Kosami K, Sasahara T and Nakamura Y (2022) Incidence of Kawasaki Disease Before and After the COVID-19 Pandemic in Japan, JAMA Pediatrics, 10.1001/jamapediatrics.2022.3756, 176:12, (1217), Online publication date: 1-Dec-2022. Hoshino S, Shibata Y, Matsubayashi J and Ae R (2022) Regional Differences in Kawasaki Disease Incidence Reduction Before and After the Onset of the Coronavirus Disease 2019 Pandemic, The Journal of Pediatrics, 10.1016/j.jpeds.2022.07.008, 250, (54-60.e5), Online publication date: 1-Nov-2022. Na J, Cho Y, Lee J, Yang S and Kim Y (2022) Immune-modulatory effect of human milk in reducing the risk of Kawasaki disease: A nationwide study in Korea, Frontiers in Pediatrics, 10.3389/fped.2022.1001272, 10 Park K, Jung C, Jeong W, Lee G, Yang J, Nam C, Kim H and Kim B (2022) Nationwide Implementation of Nonpharmaceutical Interventions During the Coronavirus Disease 2019 Pandemic Is Associated With Decreased Incidence of Pneumocystis jirovecii Pneumonia in Kidney Transplant Recipients , Open Forum Infectious Diseases, 10.1093/ofid/ofac076, 9:6, Online publication date: 1-Jun-2022. Burney J, Roberts S, DeHaan L, Shimizu C, Bainto E, Newburger J, Dominguez S, Jone P, Jaggi P, Szmuszkovicz J, Rowley A, Samuy N, Scalici P, Tremoulet A, Cayan D, Burns J, Arditi M, Szmuszkovicz J, Ashouri N, Yeh S, Michalik D, Burns J, Tremoulet A, Portman M, Newcomer C, Kurio G, McNellis A, Kim K, Ang J, Manaloor J, Rowley A, Erdem G, Bartlett A, Kumar M, Newburger J, El Feghaly R, Ansusinha E, DeBiasi R, Harahsheh A, Ronis T, Jain S, Anderson M, Dominguez S, Hite M, Jone P, Simonsen K, Chatterjee A, Truong D, Romero J, Lloyd D, Samuy N, Scalici P, Sharma K and Halasa N (2022) Epidemiological and Clinical Features of Kawasaki Disease During the COVID-19 Pandemic in the United States, JAMA Network Open, 10.1001/jamanetworkopen.2022.17436, 5:6, (e2217436) Yu H, Ni C, Xia Y, Li J, Hang B, Han C, Xu Z, Luo M, Rong X, Zhu J and Chu M (2022) Characteristics of Kawasaki Disease Before and After the COVID-19 Pandemic in a Large Pediatric Heart Disease Center, Frontiers in Pediatrics, 10.3389/fped.2022.895408, 10 Ahn J (2022) Epidemiological changes in infectious diseases during the coronavirus disease 2019 pandemic in Korea: a systematic review, Clinical and Experimental Pediatrics, 10.3345/cep.2021.01515, 65:4, (167-171), Online publication date: 15-Apr-2022. Jeong S and Jung H (2022) Effect of a Regional Outbreak of Coronavirus Disease 2019 on Kawasaki Disease in Korea, Risk Management and Healthcare Policy, 10.2147/RMHP.S359781, Volume 15, (739-745) Kang J, Jung J, Kim Y, Huh K, Hong J, Kim D, Kim M, Jung S, Kim J and Ahn J (2022) Temporal Correlation Between Kawasaki Disease and Infectious Diseases in South Korea, JAMA Network Open, 10.1001/jamanetworkopen.2021.47363, 5:2, (e2147363) Guo M, Yang K, Liu S and Kuo H (2022) Number of Kawasaki Disease Admissions Is Associated with Number of Domestic COVID-19 and Severe Enterovirus Case Numbers in Taiwan, Children, 10.3390/children9020149, 9:2, (149) Kim B, Choi A, Kim H, Oh J, Lee J, Kim S, Han J, Kim K and Kim H (2022) Changes in the Clinical Characteristics of Kawasaki Disease After Coronavirus Disease (COVID-19) Pandemic: A Database Analysis, Journal of Korean Medical Science, 10.3346/jkms.2022.37.e141, 37:20 Lin M (2022) Precision Medicine and Big Data Research of Kawasaki Disease Kawasaki Disease, 10.1007/978-981-19-2944-1_5, (39-46), . Park J, Jang J and Choi Y (2021) The impact of the COVID-19 pandemic on oral health behavior and oral symptoms in young adults, Journal of Korean Academy of Oral Health, 10.11149/jkaoh.2021.45.4.192, 45:4, (192-197), Online publication date: 30-Dec-2022. Shulman S and Rowley A (2021) An Unintended Consequence of Pandemic Control Measures: Fewer Cases of Kawasaki Disease, The Journal of Pediatrics, 10.1016/j.jpeds.2021.08.069, 239, (11-14), Online publication date: 1-Dec-2021. Ae R, Shibata Y, Kosami K, Nakamura Y and Hamada H (2021) Kawasaki Disease and Pediatric Infectious Diseases During the Coronavirus Disease 2019 Pandemic, The Journal of Pediatrics, 10.1016/j.jpeds.2021.07.053, 239, (50-58.e2), Online publication date: 1-Dec-2021. Vella L and Rowley A (2021) Current Insights Into the Pathophysiology of Multisystem Inflammatory Syndrome in Children, Current Pediatrics Reports, 10.1007/s40124-021-00257-6, 9:4, (83-92), Online publication date: 1-Dec-2021. Thrift K, Withycombe J and Temples H (2021) Is it Kawasaki Disease or Multisystem Inflammatory Syndrome in Children?, The Journal for Nurse Practitioners, 10.1016/j.nurpra.2021.08.006, 17:10, (1230-1236), Online publication date: 1-Nov-2021. Yang Y and Kuo H (2021) Public Health Interventions for COVID-19 Reduce Kawasaki Disease in Taiwan, Children, 10.3390/children8080623, 8:8, (623) June 22, 2021Vol 143, Issue 25 Advertisement Article InformationMetrics © 2021 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.121.054785PMID: 34092115 Originally publishedJune 7, 2021 KeywordsCOVID-19incidenceKawasaki diseasemucocutaneous lymph node syndromephysical distancingRepublic of KoreaPDF download Advertisement SubjectsEpidemiologyPediatricsVascular Disease